**Research Article**

*Helicobacter pylori* infection is not associated with portal hypertension-related gastrointestinal complications: A meta-analysis

Yu Kyung Jun¹,², Ji Won Kim²,³, Byeong Gwan Kim¹, Kook Lae Lee³, Yong Jin Jung³, Won Kim³, Hyun Sun Park²,³, Dong Hyeon Lee³‡, Seong-Joon Koh¹,²‡

¹ Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea, ² Laboratory of Intestinal Mucosa and Skin Immunology, SMG-SNU Boramae medical Center, Seoul, Korea, ³ Department of Internal medicine, Division of Gastroenterology, SMG-SNU Boramae medical Center, Seoul, Korea, ⁴ Department of Dermatology, SMG-SNU Boramae medical Center, Seoul, Korea

‡ These authors also contributed equally to this work.

* jel1206@snu.ac.kr (SJK); donghyeonlee83@gmail.com (DHL)

**Abstract**

Despite the importance of *Helicobacter pylori* infection and portal hypertension (PH)-associated gastrointestinal (GI) diseases, such as esophageal varices and portal hypertensive gastropathy (PHG), the impact of *H. pylori* infection on PH-related GI complications has not yet been elucidated. This meta-analysis investigated the association between *H. pylori* infection and the risk of PH-related GI complications. An electronic search for original articles published before May 2020 was performed using PubMed, EMBASE, and the Cochrane Library. Independent reviewers conducted the article screening and data extraction. We used the generic inverse variance method for the meta-analysis, and Begg’s rank correlation test and Egger’s regression test to assess publication bias. A total of 1,148 cases of *H. pylori* infection and 1,231 uninfected controls were included from 13 studies. *H. pylori* infection had no significant association with esophageal varices [relative risk (RR) = 0.96, 95% confidence interval (CI) = 0.87–1.06 for all selected studies; RR = 0.95, 95% CI = 0.84–1.07 for cohort studies; odds ratio (OR) = 0.96, 95% CI = 0.60–1.54 for case-control studies]. Although *H. pylori* infection was significantly associated with PHG in case-control studies [OR = 1.86, 95% CI = 1.17–2.96], no significant differences were found in the cohort studies [RR = 0.98, 95% CI = 0.91–1.05] or all studies combined [RR = 1.18, 95% CI = 0.93–1.52]. In conclusion, *H. pylori* infection was not associated with the risk of PH-related GI complications. Clinicians should carefully treat cirrhotic patients with PH-related GI complications, regardless of *H. pylori* infection.
Introduction

Liver cirrhosis is a disease characterized by chronic fibrosis and dysfunction of the liver. In cirrhotic patients, structural abnormalities, including hepatic vascular resistance, and functional defects, including endothelial dysfunction and increased hepatic vascular tone, increase hepatic resistance to portal blood flow and elevate portal pressure. Alterations in intrahepatic hemodynamics provoke splanchnic vasodilation as an adaptive response. As cirrhosis progresses, splanchnic vasodilation becomes too intense to have serious effects on systemic circulation. Varices and portal hypertensive gastropathy (PHG) can develop as complications of portal hypertension (PH) in patients with cirrhosis. Varices and PHG are observed in approximately 50% and 3–14% of cirrhotic patients, respectively, and can be the main causes of massive bleeding, leading to hemodynamic instability and a life-threatening disease course [1]. Therefore, controlling PH-associated GI diseases in patients with liver cirrhosis is a great challenge.

*Helicobacter pylori* can colonize the acidic gastric mucosal surface. Gastric colonization by *H. pylori* can induce peptic ulcer disease, atrophic gastritis, gastric cancer, and mucosa-associated lymphoid tissue lymphoma. *H. pylori* also contributes to non-GI disorders, such as iron-deficient anemia, vitamin B12 deficiency, and idiopathic thrombocytopenic purpura. Extragastric diseases that were previously considered to be independent of *H. pylori* have recently been found to be related to *H. pylori* infection [2,3]. Multiple liver diseases, such as chronic viral hepatitis and nonalcoholic fatty liver disease (NAFLD), are also known to be associated with *H. pylori* infection [4–6]. Many studies have demonstrated a positive relationship between *H. pylori* infection and cirrhosis, regardless of PH-related GI complications [7]. Moreover, a cirrhotic patient with a higher Model for End-stage Liver Disease (MELD) score can show higher positivity for *H. pylori* infection [8]. *H. pylori* eradication therapy can also improve hyperammonemia in patients with cirrhosis [9]. Although there are several articles regarding the presence of *H. pylori* infection in cirrhotic patients with varices or PHG, these show controversial results concerning the relationship between *H. pylori* infection and PH-related GI complications [10–20]. Therefore, we aimed to integrate articles dealing with the relationship between *H. pylori* infection and PH-related complications in patients with cirrhosis.

Materials and methods

Data sources and searches

Two authors (Y.K.J. and D.H.L.) independently carried out a comprehensive systematic search for published articles from inception to May 2020 using PubMed, EMBASE, and the Cochrane Library. The search was limited to human studies without language restrictions. Search terms included “Helicobacter,” “pylori,” “pyloridis,” “Helicobacter pylori,” or “Campylobacter pylori” and “liver cirrhosis,” “liver fibrosis,” “hepatic fibrosis,” “liver failure,” “hepatic failure,” “esophageal varix,” “varix,” “variceal,” or “portal hypertensive gastropathy” which are described in S1 Text. We manually searched major international gastroenterology and hepatology conference abstracts and the references of the selected articles. Additionally, we found articles through internet searches to identify further relevant studies. The current study was conducted following the Preferred Reporting Items for Systematic review and Meta-Analysis protocols (PRISMA) guidelines [21].

Selection criteria

Studies that met the following eligibility criteria were included: 1) observational studies, including cohort and case-control studies; 2) studies that evaluated the relationship between
\textit{H. pylori} infection and PH-related GI complications; 3) appropriate diagnostic tests for \textit{H. pylori} infection conducted prior to the evaluation of PH-related GI complications; and 4) available raw data reported in the comparison arms.

Studies that did not include original articles were excluded. Also, studies were excluded if they were case studies, had no control group, or were not performed on human subjects. We excluded articles that did not explicitly state institutes or hospitals where the research was performed. When duplicated publications were identified, we included the most recent and thorough articles.

**Data extraction and outcomes**

Data extraction was conducted independently by two authors (Y.K.J. and D.H.L.). The following data were collected from the included studies: first author, year of publication, study design, demographic and clinical information of the study patients (age, sex, ethnicity, and etiology of liver cirrhosis), methods of \textit{H. pylori} detection, and outcome results in patients with or without \textit{H. pylori} infection.

The retrieved articles were independently reviewed by fully qualified investigators (Y.K.J., D.H.L., and S.J.K.), and disagreements were resolved through discussions among investigators. The Newcastle-Ottawa quality assessment Scale (NOS), which was developed as a judgment tool for the quality of nonrandomized studies such as case-control or cohort studies in meta-analyses, was used to evaluate the quality of the selected studies [22]. The questions in the NOS questionnaire were categorized as items of selection, comparability, and exposure, and were scored using stars. Studies scoring 8–9 stars were categorized as high-quality, 6–7 stars as moderate-quality, and 0–5 stars as low-quality [23].

**Statistical analysis**

All statistical analyses were performed using Stata software (version 15.0; Stata Corporation, College Station, TX) and R (version 4.0.1; The R Project for Statistical Computing, Vienna, Austria). The odds ratio (OR), relative risk (RR), and 95% confidence interval (CI) were considered to be the effect sizes. We used the unadjusted OR and RR values calculated from the raw data. Considering the low incidence of PH-related GI complications in \textit{H. pylori}-infected patients, we assumed that the ORs were similar to RRs. The generic inverse variance method was used to combine the results across studies. Heterogeneity among studies was assessed using the \( I^2 \) statistics test considering low heterogeneity (<25%), moderate heterogeneity (25–75%), and high heterogeneity (>75%). Subgroup analyses based on NOS information were also performed. The probability of publication bias was assessed using the Begg’s rank correlation test and Egger’s regression test. Statistical significance was set at \( P < 0.05 \).

**Results**

**Literature search**

Through the database search, 4,429 potentially eligible studies were identified (752 journals from PubMed, 3,381 journals from EMBASE, and 296 journals from the Cochrane library). We excluded 498 duplicated studies. After evaluating study titles and abstracts, 3,788 studies and 121 studies were excluded. After a full-length article review, 11 studies were excluded, and other 11 studies were included. Among these excluded studies, 2 studies were not accessible, 2 studies did not have relevant content, and 7 studies did not report the complete outcomes of interest. Two studies were identified after additional searches. Finally, 13 studies (8 cohort
studies and 5 case-control studies) were included in the meta-analysis [10–13,15–19,24,25]. The literature search and selection flow diagram are described in Fig 1.

Study characteristics and quality

The baseline characteristics and quality assessments of the 13 trials are summarized in Table 1. A total of 2,379 patients were included in the meta-analysis. H. pylori-specific serum
immunoglobulin G was most frequently used for the diagnosis of *H. pylori* infection [10,12,14,17,19,25]. The common causes of cirrhosis were viral hepatitis and alcoholic liver disease. Two articles [11,26] did not include patients with cirrhosis caused by hepatitis virus infection. Five articles gave the mean age of *H. pylori*-positive patients and *H. pylori*-negative patients, respectively [12,13,16,19,20]. Mean age of *H. pylori*-positive patients was 54.1 ± 10.8 years and that of *H. pylori*-negative patients was 54.8 ± 9.4 years. There was no significant age difference according to *H. pylori* infection. The median NOS score of the trials that were included was 7 (range 5–8), and we considered 5 of 13 trials to be of high methodological quality (S1 and S2 Tables).

### The relationship between *H. pylori* infection and the risk of PH-related GI complications

The meta-analysis results of the association between *H. pylori* infection and PH-related GI complications are shown in Table 2. *H. pylori* infection was not significantly associated with esophageal varices (RR = 0.96, 95% CI = 0.87–1.06). Similarly, there was no association between *H. pylori* infection and PHG (RR = 1.01, 95% CI = 0.94–1.08). Subgroup analyses based on information on the study design and NOS were conducted. Figs 2 and 3 show the unadjusted RR/OR and 95% CI of PH-related GI complications by *H. pylori* infection in cohort studies and case-control studies, respectively. There was no meaningful relationship

### Table 1. Main characteristics of all studies in the meta-analysis (ordered by publication year and study design).

| Study          | Country | Study design | Diagnostic tool for *H. pylori* | Etiology of LC* | End points | Male (%) | Mean age | *H. pylori*-infected n (+ vs. -) | NOS |
|----------------|---------|--------------|-------------------------------|-----------------|------------|----------|----------|----------------------------------|-----|
| Wu et al., 1995 [10] | Taiwan | Case-control | Serum IgG                     | HBV, HCV, HBV-HDV | EV         | 73.3     | 51.5     | 82 vs. 120                       | 6   |
| Balan et al., 1996 [11] | UK     | Cohort       | Histology                     | Alc, PBC        | PHG        | 58       | 53*      | 20 vs. 30                        | 8   |
| Bahnacy et al., 1997 [25] | Hungary | Case-control | Serum IgG                     | Alc, Hep, PBC, PVB | PHG        | 73.3     | 49.1     | 23 vs. 67                        | 5   |
| Tsai, 1998 [12] | Taiwan | Cohort       | Serum IgG, CLO, HBV, HCV, Alc, | PHG              | EV         | 66.2     | 54.4     | 99 vs. 22                        | 8   |
| McCormick et al., 1999 [24] | UK     | Cohort       | Histology, Alc, PVB, Schi, congenital | PHG          | 53.8     | 51.5     | 22 vs. 71                        | 7   |
| Yeh et al., 2001 [13] | Taiwan | Cohort       | 13C-UBT                       | HBV, Alc, HCV, HBV-HCV | EV, PHG | 72.5 | 57.4 | 57 vs. 52 | 8 |
| Chen et al., 2002 [14] | Taiwan | Case-control | Serum IgG                     | HBV, HCV, Alc   | EV         | 76.6     | 64.8*    | 42 vs. 57                        | 5   |
| Arafa et al., 2003 [19] | Japan  | Cohort       | 13C-UBT, Serum IgG            | HBV, HCV, Alc   | PHG        | 78.3     | 63       | 31 vs. 29                        | 8   |
| Urso et al., 2006 [15] | Italy  | Cohort       | Histology, 13C-UBT            | HCV             | PHG        | 58.7     | 69.7     | 26 vs. 83                        | 7   |
| Abbas et al., 2014 [16] | Pakistan | Cohort     | Histology, PCR                | HCV, HBV, HBV-HDV | EV, PHG | 65.7     | 50.3     | 87 vs. 53                        | 7   |
| Sathar et al., 2014 [17] | India  | Case-control | Serum IgG                     | Alc, HBV, HCV, AIH | PHG        | 66.4     | 53.45    | 50 vs. 90                        | 6   |
| Huang and Cui, 2017 [18] | China  | Case-control | 13C-UBT                       | HBV             | PHG        | 50.2     | 52.5     | 339 vs. 269                      | 5   |
| Abdel-Razik et al., 2020 [20] | Egypt  | Cohort       | fecal antigen                 | HBV, HCV       | EV, PHG    | 72.4     | 54.1     | 270 vs. 288                      | 8   |

*H. pylori*, *Helicobacter pylori*; LC, liver cirrhosis; n, number of patients; NOS, Newcastle-Ottawa scale; UK, United Kingdom; IgG, immunoglobulin G; CLO, *Campylobacter*-like organism; UBT, urea breath test; Alc, alcohol; PBC, primary biliary cholangitis; Hep, viral hepatitis; PVB, portal vein block; Schi, schistosomiasis; AIH, autoimmune hepatitis; EV, esophageal varices; PHG, portal hypertensive gastropathy.

*Etiologies are sorted by largest number of patients.*

*Median age.*

https://doi.org/10.1371/journal.pone.0261448.t001
Table 2. Meta-analysis of relationship between Helicobacter pylori infection and portal hypertension-related gastrointestinal complications.

| PH-related GI complications | Study design | Studies, N | Heterogeneity | M | Effect size |
|-----------------------------|--------------|------------|---------------|---|-------------|
|                             |              |            | $I^2$ (%) | $P_{H}$ | RR | OR | 95% CI | $P_{ES}$ |
| Esophageal varix            | Cohort study | 4          | 0.4460 | F | 0.95 | – | 0.84–1.07 | 0.4188 |
|                             | Case-control study | 2 | 0.7919 | F | – | 0.96 | 0.60–1.54 | 0.8738 |
|                             | Total        | 6          | 0.7258 | F | 0.96 | – | 0.87–1.06 | 0.446 |
|                             |              |            | 0.7236 | – | 0.93 | 0.73–1.19 | 0.5772 |
| Portal hypertensive gastropathy | Cohort study | 7          | 0.6557 | F | 0.98 | – | 0.91–1.05 | 0.5489 |
|                             | Case-control study | 3 | 0.4112 | F | – | 1.86 | 1.17–2.96 | 0.0092 |
|                             | Total        | 10         | 0.1737 | F | 1.01 | – | 0.94–1.08 | 0.8825 |
|                             |              |            | 24.6   | 0.2173 | – | 1.18 | 0.93–1.52 | 0.2177 |

PH, portal hypertension; GI, gastrointestinal; N, number; $P_{H}$, $p$-value for heterogeneity; M, model for meta-analysis; F, fixed-effect model; RR, relative risk; OR, odds ratio; $P_{ES}$, $p$-value for effect size.

https://doi.org/10.1371/journal.pone.0261448.t002

Study

**Esophageal varix**
- Tsai, 1998: 1.00 [0.80; 1.24] 8.5%
- Yeh et al., 2001: 1.11 [0.80; 1.54] 3.7%
- Abbas et al., 2014: 0.82 [0.66; 1.03] 7.9%
- Abdel-Razik et al., 2020: 0.97 [0.76; 1.24] 6.7%

**Fixed effect model**
- Heterogeneity: $I^2 = 0\%$, $p = 0.45$
- RR: 0.95 [0.84; 1.07] 26.7%

**Portal hypertensive gastropathy**
- Balan et al., 1996: 0.75 [0.48; 1.18] 2.0%
- McCormick et al., 1999: 0.93 [0.78; 1.11] 12.7%
- Yeh et al., 2003: 0.86 [0.51; 1.46] 1.5%
- Arafa et al., 2003: 0.89 [0.59; 1.32] 2.5%
- Urso et al., 2006: 1.04 [0.91; 1.18] 22.3%
- Abbas et al., 2014: 0.96 [0.86; 1.09] 28.7%
- Abdel-Razik et al., 2020: 1.19 [0.85; 1.66] 3.6%

**Fixed effect model**
- Heterogeneity: $I^2 = 0\%$, $p = 0.66$
- RR: 0.98 [0.91; 1.05] 73.3%

**Fixed effect model**
- Heterogeneity: $I^2 = 0\%$, $p = 0.73$
- Residual heterogeneity: $I^2 = 0\%$, $p = 0.66$
- RR: 0.97 [0.91; 1.03] 100.0%

Fig 2. Unadjusted relative risk and 95% confidence interval of portal hypertension-related gastrointestinal complications by Helicobacter pylori infection in eight cohort studies. RR, relative risk; CI, confidence interval.

https://doi.org/10.1371/journal.pone.0261448.g002
between esophageal varices and *H. pylori* in either cohort (RR = 0.95, 95% CI = 0.84–1.07) or case-control studies (OR = 0.96, 95% CI = 0.60–1.54). *H. pylori* infection was shown to be unrelated to PHG in cohort studies (RR = 0.98, 95% CI = 0.91–1.05), but in case-control studies of the relationship between *H. pylori* and PHG, it was noted that there was some relationship between *H. pylori* infection and PHG (OR = 1.86, 95% CI = 1.17–2.96).

For subgroup analysis, we selected highly qualified articles with NOS > 7 and analyzed them in Fig 4. Five cohort studies were included in the subgroup analysis, and all case-control studies were excluded. There was no significant correlation between *H. pylori* infection and PH-related GI complications in patients with cirrhosis (RR = 0.99, 95% CI = 0.88–1.12).

### Heterogeneity analysis, sensitivity analysis, and publication bias

There was no heterogeneity found (P_H > 0.10) in the pooled estimates of cirrhotic patients with varices. The corresponding pooled ORs were not significantly influenced by omitting any single study, as shown in S3 Table. Publication bias in this study was unremarkable. All P-values obtained from I^2 (P_H), Begg’s (P_Begg) and Egger’s methods (P_Egg) are shown in Tables 2 and 3.

### Discussion

The relationship between *H. pylori* infection and PH-related GI complications is not yet well-understood, although a meta-analysis performed by Feng et al. [27] revealed a high prevalence of *H. pylori* infection in patients with cirrhosis [10,11]. Unlike previous meta-analyses, we analyzed whether *H. pylori* infection contributes to PH-related GI complications in patients with liver cirrhosis. In the present study, it was found that PH-associated GI complications were not related to gastric colonization by *H. pylori*. We believe that this study is the first study to demonstrate the association between *H. pylori* infection and PH-related GI complications.

Many studies have suggested a strong relationship between *H. pylori* infection and liver cirrhosis [18,28–31]. The rate of *H. pylori* infection was higher in chronic hepatitis patients than in healthy controls, and cirrhotic patients with *H. pylori* infection had poorer outcomes than

---

### Table 1: Meta-analysis of the relationship between *H. pylori* infection and portal hypertension complications

| **Study**                  | **OR**  | **[95% CI]** | **Weight** |
|----------------------------|---------|--------------|------------|
| **Esophageal varix**       |         |              |            |
| Wu et al., 1995            | 1.01    | [0.57; 1.79  | 33.3%      |
| Chen et al., 2002          | 0.88    | [0.38; 2.01] | 16.1%      |
| Fixed effect model         | 0.96    | [0.60; 1.54] | 49.4%      |
| Heterogeneity: I^2 = 0% , p = 0.79 |         |              |            |
| **Portal hypertensive gastropathy** |         |              |            |
| Bahnay et al., 1997        | 1.06    | [0.41; 2.75] | 12.2%      |
| Sathar et al., 2014        | 2.13    | [1.05; 4.33] | 22.0%      |
| Huang and Cui, 2017        | 2.34    | [1.03; 5.33] | 16.3%      |
| Fixed effect model         | 1.86    | [1.17; 2.96] | 50.6%      |
| Heterogeneity: I^2 = 0% , p = 0.41 |         |              |            |
| Fixed effect model         | 1.34    | [0.96; 1.87] | 100.0%     |
| Heterogeneity: I^2 = 29% , p = 0.23 |         |              |            |
| Residual heterogeneity: I^2 = 0% , p = 0.60 |         |              |            |

### Fig 3. Unadjusted odds ratio and 95% confidence interval of portal hypertension-related gastrointestinal complications by *Helicobacter pylori* infection in five case-control studies. OR, odds ratio; CI, confidence interval.

https://doi.org/10.1371/journal.pone.0261448.g003
those without. The positivity of the *H. pylori* cytotoxin-associated gene A (CagA) gene in liver tissue is associated with the severity of hepatic fibrosis. Moreover, *H. pylori* infection can lead to and aggravate NAFLD [6,32]. The incidence of hepatocellular carcinoma increases when chronic hepatitis C patients are co-infected with *H. pylori* [30]. *H. pylori* eradication greatly improves cirrhosis and cirrhotic complications [20,33,34].

The relationship between PH-related GI complications and *Helicobacter pylori* infection in highly qualified studies is

---

### Table 3. Publication bias of studies conducted by Begg’s rank correlation test and Egger’s regression test.

| PH-related GI complication          | Study design          | Studies, N | Publication bias |
|------------------------------------|-----------------------|------------|------------------|
|                                    |                       |            |                  |
| **Esophageal varix**               | **Cohort study**      | 4          | 0.497            | 0.405            |
|                                    | **Case-control study**| 2          | 0.317            |                  |
|                                    | **Total**             | 6          | 0.573 (RR)       | 0.762 (RR)       |
|                                    | **Residual heterogeneity** |          | 0.573 (OR)       | 0.425 (OR)       |
| **Portal hypertensive gastropathy**| **Cohort study**      | 7          | 0.453            | 0.459            |
|                                    | **Case-control study**| 3          | 0.602            | 0.423            |
|                                    | **Total**             | 10         | 0.655 (RR)       | 0.480 (RR)       |
|                                    |                       |            | 0.128 (OR)       | 0.220 (OR)       |

*PH, portal hypertension; GI, gastrointestinal; N, number; P<sub>Begg</sub>, p-value for Begg’s test; P<sub>Egger</sub>, p-value for Egger’s test.*

https://doi.org/10.1371/journal.pone.0261448.t003
form [36,37]. *H. pylori* can survive in acidic environment, and its growth was limited in neutral pH [38,39]. The range of gastric pH in the general population is 0.3–2.9 [40]. However, gastric pH in PHG patients is higher than that in the general population, and the more severe the PHG, the lesser the gastric acidity [41]. Gastric vascular congestion in PHG may suppress *H. pylori* colonization. The severity of gastric vascular congestion is not associated with the possibility of *H. pylori* infection [42–44].

*H. pylori* infection can be suppressed in patients with PH, including varix and PHG, although *H. pylori* infection can increase in patients with cirrhosis and result in poor prognosis. Our recent study revealed an insignificant relationship between PH-related GI complications and *H. pylori* infection as in the previous studies. Analysis using three case-control studies showed the possibility of a positive relationship between PH-related GI complications and *H. pylori* infection. However, case-control studies are less reliable than cohort studies in terms of evidence-based medicine. Moreover, the selected case-control studies had a lower quality than cohort studies. Subgroup analysis, including only articles with NOS>7, failed to show a meaningful relationship between *H. pylori* infection and PH-related GI complications. However, in a cohort study of patients with cirrhosis, patients with *H. pylori* infection had a poor prognosis, including PH-related GI complications, as compared with those without [20].

Although there have been previous studies on the relationship between *H. pylori* infection and PH-related complications, this meta-analysis may be the first to establish a comprehensive and reliable analysis. Prior studies covered only one or a few etiologies of chronic liver disease, but this study handles multiple etiologies of cirrhosis, including viral hepatitis, alcoholic hepatitis, autoimmune hepatitis, and even PBC. This meta-analysis deals with all *H. pylori* diagnostic techniques used in actual clinical practice. In addition, the studies included in this meta-analysis have similarities in the composition of sex and gender of the participants. There are low to moderate grades of heterogeneity and inconsistency across studies on PHG. Also, there was no detectable publication bias according to Begg’s rank correlation test and Egger’s regression test.

However, this study has some limitations and requires careful consideration when interpreting the results of the investigation. The total number of articles included in the meta-analysis was relatively small (13 articles). In addition, 5 out of 13 articles were case-control studies; therefore, there are only 8 cohort studies with high reliability. Because meta-analyses comprise already published articles, their conclusions are affected by the number and quality of the chosen studies. If more highly qualified original articles on the subject of the connection between *H. pylori* infection and PH-related GI complications are reported, more influential and reliable meta-analyses will be available. A meta-analysis that deals with the relationship between *H. pylori* infection and the risk of bleeding due to PH-related GI complications is also required because there are conflicting reports about the relationship between variceal bleeding and *H. pylori* infection [45,46].

In summary, our study demonstrated that gastric colonization of *H. pylori* patients with cirrhosis is unlikely to be attributed to the development of PH-associated GI complications. Knowing that *H. pylori* infection is not associated with PH-related GI complications in cirrhosis patients will help clinicians treat PH-related GI complications and *H. pylori*-induced gastritis in cirrhosis patients. Clinicians can treat PH-related GI complications in patients with cirrhosis, regardless of *H. pylori* infection.

**Supporting information**

S1 Table. Quality assessment of included case-control studies by the Newcastle-Ottawa scale.

(DOCX)
S2 Table. Quality assessment of included cohort studies by the Newcastle-Ottawa scale. (DOCX)

S3 Table. Sensitivity analysis. (DOCX)

S4 Table. PRISMA checklist. (DOCX)

S1 Text. Supplementary methods. Search strategies for PubMed, EMBASE and the Cochrane Library. (DOCX)

Author Contributions

Conceptualization: Ji Won Kim, Yong Jin Jung, Won Kim, Hyun Sun Park, Dong Hyeon Lee, Seong-Joon Koh.

Data curation: Yu Kyung Jun.

Formal analysis: Yu Kyung Jun, Dong Hyeon Lee.

Funding acquisition: Hyun Sun Park, Dong Hyeon Lee.

Methodology: Hyun Sun Park, Dong Hyeon Lee.

Resources: Yu Kyung Jun.

Supervision: Ji Won Kim, Byeong Gwan Kim, Kook Lae Lee, Dong Hyeon Lee, Seong-Joon Koh.

Validation: Ji Won Kim.

Writing – original draft: Yu Kyung Jun.

Writing – review & editing: Yu Kyung Jun, Dong Hyeon Lee, Seong-Joon Koh.

References

1. Merli M, Nicolini G, Angeloni S, Gentili F, Attili AF, Riggio O. The natural history of portal hypertensive gastropathy in patients with liver cirrhosis and mild portal hypertension. Am J Gastroenterol. 2004; 99(10):1959–65. Epub 2004/09/28. https://doi.org/10.1111/j.1572-0241.2004.40246.x PMID: 15447756.

2. Mansour L, El-Kalla F, Kobtan A, Abd-Elsalam S, Yousef M, Soliman S, et al. Helicobacter pylori may be an initiating factor in newly diagnosed ulcerative colitis patients: A pilot study. World journal of clinical cases. 2018; 6(13):641. https://doi.org/10.12998/wjcc.v6.i13.641 PMID: 30430119

3. Pellicano R, Ianiro G, Fagoonee S, Settanni CR, Gasbarrini A. Extragastric diseases and Helicobacter pylori. Helicobacter. 2020; 25:e12741. https://doi.org/10.1111/hel.12741 PMID: 32918343

4. Wijarnpreecha K, Thongprayoon C, Panjawatana P, Manatsathit W, Jaruvongvanich V, Ungprasert P. Helicobacter pylori and Risk of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. J Clin Gastroenterol. 2018; 52(5):386–91. Epub 2017/01/19. https://doi.org/10.1097/MCG.0000000000000784 PMID: 28098578.

5. Okushin K, Tsutsumi T, Ikeuchi K, Kado A, Enooku K, Fujinaga H, et al. Helicobacter pylori infection and liver diseases: Epidemiology and insights into pathogenesis. World J Gastroenterol. 2018; 24(32):3617–25. Epub 2018/09/01. https://doi.org/10.3748/wjg.v24.i32.3617 PMID: 30166857; PubMed Central PMCID: PMC6113725.

6. Abdel-Razik A, Mousa N, Shabana W, Refaey M, Elhelaly R, Elzehery R, et al. Helicobacter pylori and non-alcoholic fatty liver disease: A new enigma? Helicobacter. 2018; 23(6):e12537. https://doi.org/10.1111/hel.12537 PMID: 30246507

7. Feng H, Zhou X, Zhang G. Association between cirrhosis and Helicobacter pylori infection: a meta-analysis. European journal of gastroenterology & hepatology. 2014; 26(12):1309–19. https://doi.org/10.1097/MEG.0000000000002220 PMID: 25304251
8. Pati G, Singh A, Narayan J, Behera M, Sahu M, Mishra D, et al. Liver Cirrhosis and Concomitant Gastric Helicobacter Pylori Infection. Microbes and Infectious Diseases. 2020.

9. Miyaji H, Ito S, Azuma T, Ito Y, Yamazaki Y, Ohtaki Y, et al. Effects of Helicobacter pylori eradication therapy on hyperammonaemia in patients with liver cirrhosis. Gut. 1997; 40(6):726–30. https://doi.org/10.1136/gut.40.6.726 PMID: 9245925

10. Wu CS, Lin CY, Liaw YF. Helicobacter pylori in cirrhotic patients with peptic ulcer disease: a prospective, case controlled study. Gastrointest Endosc. 1995; 42(5):424–7. Epub 1995/11/01. https://doi.org/10.1016/s0016-5107(95)70044-7 PMID: 8566632.

11. Balan KK, Jones AT, Roberts NB, Pearson JP, Critchley M, Jenkins SA. The effects of Helicobacter pylori colonization on gastric function and the incidence of portal hypertensive gastropathy in patients with cirrhosis of the liver. Am J Gastroenterol. 1996; 91(7):1400–6. Epub 1996/07/01. PMID: 8678003.

12. Tsai CJ. Helicobacter pylori infection and peptic ulcer disease in cirrhosis. Dig Dis Sci. 1998; 43 (6):1219–25. Epub 1998/07/04. https://doi.org/10.1023/a:1018899506271 PMID: 9635611.

13. Yeh JL, Peng YC, Chen GH, Chow WK, Chang FY, Lin HC, et al. Role of Helicobacter pylori in cirrhotic patients with dyspepsia: a 13C-urea breath test study. Adv Ther. 2001; 18(3):140–50. Epub 2001/09/27. https://doi.org/10.1016/BF02850302 PMID: 11571826.

14. Chen CT, Wang TF, Chan CC, Lee FY, Chang FY, Lin HC, et al. Role of chronic Helicobacter pylori infection in hyperdynamic circulation of cirrhotic patients. Hepatogastroenterology. 2002; 49(43):208–12. Epub 2002/04/11. PMID: 11941956.

15. Urso G, Interlandi D, Puglisi M, Abate G, Bertino G, Raciti C, et al. Role of Helicobacter pylori in patients with portal hypertensive gastropathy by liver cirrhosis hepatitis C virus-related. Minerva Gastroenterol Dietol. 2006; 52(3):303–8. Epub 2006/09/15. PMID: 16971874.

16. Abbas Z, Yakoob J, Usman MW, Shakir T, Hamid S, Jafri W. Effect of Helicobacter pylori and its virulence factors on portal hypertensive gastropathy and interleukin (IL)-8, IL-10, and tumor necrosis factor-alpha levels. Saudi J Gastroenterol. 2014; 20(2):120–7. Epub 2014/04/04. https://doi.org/10.4103/1319-3767.129477 PMID: 24705150; PubMed Central PMCID: PMC3987152.

17. Sathar SA, Kunnatharambil SG, Sreen S, Narayanan P, Vinayakumar KR. Helicobacter pylori infection with cirrhosis of the liver. Am J Gastroenterol. 1996; 91(7):1400–6. Epub 1996/07/01. PMID: 8678003.

18. Huang J, Cui J. Evaluation of Helicobacter pylori Infection Patients in Patients with Chronic Hepatic Disease. Chin Med J (Engl). 2017; 130(2):149–54. Epub 2017/01/17. https://doi.org/10.4103/0366-6999.197980 PMID: 28091405; PubMed Central PMCID: PMC5282670.

19. Arafa UA, Fujirava Y, Higuchi K, Shiba M, Uchida T, Watanabe T, et al. No additive effect between Helicobacter pylori infection and portal hypertensive gastropathy on inducible nitric oxide synthase expression in gastric mucosa of cirrhotic patients. Digestive diseases and sciences. 2003; 48(1):162–8. https://doi.org/10.1023/a:1021707103590 PMID: 12645804

20. Abdel-Razik A, Mousa N, Elhelaly R, Elzehery R, Hanas AS, Abdelsalam M, et al. Helicobacter pylori as an Initiating Factor of Complications in Patients With Cirrhosis: A Single-Center Observational Study. Frontiers in medicine. 2020; 7:96. https://doi.org/10.3389/fmed.2020.00096 PMID: 32266280

21. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. Brmj. 2015; 349. https://doi.org/10.1136/bmj.g7647 PMID: 25555855

22. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603–5. Epub 2010/07/24. https://doi.org/10.1007/s10654-010-9491-z PMID: 20652370.

23. Ellis R, Blyth R, Arnold N, Miner-Williams W. Is there a relationship between impaired median nerve excursion and carpal tunnel syndrome? J Hand Ther. 2017; 30(1):3–12. Epub 2016/10/04. https://doi.org/10.1016/j.jht.2016.09.002 PMID: 27692791.

24. McCormick PA, Sankey EA, Cardin F, Dhillon AP, McIntyre N, Burroughs AK. Congestive gastropathy and Helicobacter pylori: an endoscopic and morphometric study. Gut. 1991; 32(4):351–4. Epub 1991/04/01. https://doi.org/10.1136/gut.32.4.351 PMID: 2026332; PubMed Central PMCID: PMC1379069.

25. Bahnacy A, Kupcsulik P, Eles Z, Jàray B, Flautner L. Helicobacter pylori and congestive gastropathy. Zeitschrift fur Gastroenterologie. 1997; 35(2):109–12. PMID: 9066100

26. McCormick P, Sankey E, Cardin F, Dhillon A, McIntyre N, Burroughs A. Congestive gastropathy and Helicobacter pylori: an endoscopic and morphometric study. Gut. 1991; 32(4):351–4. https://doi.org/10.1136/gut.32.4.351 PMID: 2026332

27. Feng H, Zhou X, Zhang G. Association between cirrhosis and Helicobacter pylori infection: a meta-analysis. Eur J Gastroenterol Hepatol. 2014; 26(12):1309–19. Epub 2014/10/12. https://doi.org/10.1097/MEG.0000000000000220 PMID: 25304251.
28. Ponzetto A, Pellicano R, Leone N, Bertutti M, Turrini F, Rizzetto M. Helicobacter pylori seroprevalence in cirrhotic patients with hepatitis B virus infection. Neth J Med. 2000; 56(6):206–10. Epub 2000/05/24. https://doi.org/10.1016/s0300-2977(00)00033-4 PMID: 10821975.

29. Wang J, Chen RC, Zheng YX, Zhao SS, Li N, Zhou RR, et al. Helicobacter pylori infection may increase the risk of progression of chronic hepatitis B disease among the Chinese population: a meta-analysis. Int J Infect Dis. 2016; 50:30–7. Epub 2016/07/28. https://doi.org/10.1016/j.ijid.2016.07.014 PMID: 27457918.

30. Wang J, Li WT, Zheng YX, Zhao SS, Li N, Huang Y, et al. The Association between Helicobacter pylori Infection and Chronic Hepatitis C: A Meta-Analysis and Trial Sequential Analysis. Gastroenterol Res Pract. 2016; 2016:8780695. Epub 2016/02/24. https://doi.org/10.1155/2016/8780695 PMID: 26904112; PubMed Central PMCID: PMC4745339.

31. Esmat G, El-Bendary M, Zakarya S, Ela MA, Zalata K. Role of Helicobacter pylori in patients with HCV-related chronic hepatitis and cirrhosis with or without hepatocellular carcinoma: possible association with disease progression. J Viral Hepat. 2012; 19(7):473–9. Epub 2012/06/09. https://doi.org/10.1111/j.1365-2893.2011.01567.x PMID: 22676359.

32. Wijarnpreecha K, Thongprayoon C, Panjawatana P, Jaruvongvanich V, Ungprasert P. Helicobacter pylori and risk of nonalcoholic fatty liver disease. Journal of clinical gastroenterology. 2018; 52(5):386–91. https://doi.org/10.1097/MCG.0000000000000784 PMID: 28998578.

33. Shawcross DL, Wright GA, Stadlbauer V, Hodges SJ, Davies NA, Wheeler-Jones C, et al. Ammonia impairs neutrophil phagocytic function in liver disease. Hepatology. 2008; 48(4):1202–12. Epub 2008/08/13. https://doi.org/10.1002/hep.22474 PMID: 18857182.

34. Gabele E, Dostert K, Hofmann C, Wiest R, Scholmerich J, Hellerbrand C, et al. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol. 2011; 55(6):1391–9. Epub 2011/06/28. https://doi.org/10.1016/j.jhep.2011.02.035 PMID: 21703208.

35. Bosch J, Pizcueta P, Feu F, Fernández M, García-Pagán JC. Pathophysiology of portal hypertension. Gastroenterology Clinics of North America. 1992; 21(1):1–14.

36. Cole S, Khartonov V, Guiney D. Effect of nitric oxide on Helicobacter pylori morphology. The Journal of infectious diseases. 1999; 180(5):1713–7. https://doi.org/10.1086/315079 PMID: 10515839.

37. Beck K-F, Eberhard W, Frank S, Huwiler A, Messmer U, Muhl H, et al. Inducible NO synthase: role in cellular signalling. Journal of Experimental Biology. 1999; 202(6):645–53. PMID: 10021318.

38. Abadi ATB. Strategies used by helicobacter pylori to establish persistent infection. World journal of infectious diseases. 1999; 180(5):1713–7. https://doi.org/10.1086/315079 PMID: 10515839.

39. Ansari S, Yamaoka Y. Survival of Helicobacter pylori in gastric acidic territory. Helicobacter. 2017; 22(4):e12386. https://doi.org/10.1111/ hel.12386 PMID: 2842047.

40. Ayazi S, Leers JM, Oezcelik A, Abate E, Peyre CG, Hagen JA, et al. Measurement of gastric pH in ambulatory esophageal pH monitoring. Surgical endoscopy. 2009; 23(9):1968–73. https://doi.org/10.1007/s00464-008-0218-0 PMID: 19067071.

41. Rohmat AS, Makmun D, Hasan I. Gastric pH Comparison Between Mild and Severe Cirrhotic Portal Hypertensive Gastropathy. The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy. 2014; 15(2):78–82.

42. Parikh S, Desai S, Prabhu S, Trivedi M, Shankaran K, Bhukwala F, et al. Congestive gastropathy: Factors influencing development, endoscopic features, Helicobacter pylori infection, and microvessel changes. American Journal of Gastroenterology (Springer Nature). 1994; 89(7).

43. Bahnacy A, Kupcsulik P, Eles Z, Jaray B, Flautner L. Helicobacter pylori infection on esophagogastric variceal bleeding in patients with liver cirrhosis and portal hypertension. Journal of gastroenterology and hepatology. 2013; 28(9):1444–9. https://doi.org/10.1111/jgh.12221 PMID: 23577833.